GlassScriptPhysician profile
Stephanie Kirk
NPI 1013314442
$2,941.74
in general payments reported to CMS, 2019-2025
23 companies · $682 in 2025
The $682 reported for 2025 was more than what 77% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $780 · 2022: $700 · 2023: $269 · 2024: $511 · 2025: $682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,462.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,462.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $625.25 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $463.21 | 2021-2024 | Spiriva Respimat, Stiolto Respimat |
| Glaxosmithkline, LLC. | $424.40 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $295.80 | 2021-2024 | |
| Novo Nordisk INC | $177.35 | 2021-2025 | Rybelsus, Ozempic |
| Astellas Pharma US INC | $149.14 | 2021-2022 | |
| Abbvie INC. | $119.10 | 2021-2025 | |
| Amgen INC. | $117.46 | 2023-2025 | Repatha, Evenity, Prolia |
| E.R. Squibb & Sons, L.L.C. | $96.63 | 2021-2022 | |
| Lilly USA, LLC | $63.13 | 2023-2025 | Mounjaro, Trulicity, Zepbound |
| Madrigal Pharmaceuticals | $55.56 | 2025 | Rezdiffra |
| Sumitomo Pharma America, INC. | $54.47 | 2024-2025 | Gemtesa |
| Exact Sciences Corporation | $52.57 | 2024-2025 | Cologuard Collection Kit |
| Edwards Lifesciences Corporation | $44.96 | 2024-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Insulet Corporation | $31.74 | 2023 | Omnipod |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $29.27 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Dexcom, INC. | $23.64 | 2024 | Dexcom G6 Transmitter |
| Abbott Laboratories | $22.46 | 2022 | |
| Mylan Specialty L.P. | $22.16 | 2022 | |
| Janssen Pharmaceuticals, INC | $21.14 | 2021 | |
| Sanofi Pasteur INC. | $18.28 | 2025 | |
| Sanofi-Aventis U.S. LLC | $17.61 | 2025 | |
| Ascend Therapeutics US, LLC | $16.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Kirk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.